Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1310_Библиотеки_им_академика_М_И_Перельмана.pdf
Index
Note: Page numbers followed by f and t indicate figures and tables respectively
A
Abdominal compartment syndrome, 439
Ablative techniques, 22
Abnormal pancreatico biliary junction (APBJ),
219, 220
Accessory right hepatic artery (ARHA), 290,
292
Acinar mantle cells, 424
Acute cholecystitis (AC),
203, 205, 208
Acute gangrenous cholecystitis, 204
Acute pancreatitis, 386, 386t, 387, 390, 403,
427, 429
antibiotics for prophylaxis for, 432t
recurrent, 414–415, 416
Adenocarcinoma. See also Pancreatic
adenocarcinoma; Pancreatic ductal
adenocarcinoma
cystadenocarcinoma, 29
IBCC, 29
Alcohol abuse, 389, 390, 391, 403
Alkaline phosphatase (ALK), 128, 132
Alpha-fetoprotein (AFP), 14, 85, 128
American Gastroenterological Association
(AGA), 362
American Hepato-Pancreato-Biliary
Association/Society of Surgical
Oncology, 376
American Joint Committee on Cancer (AJCC),
cancer staging, 92t, 300, 301t
Anastomosis, 135, 170, 221, 230, 231, 330,
394
Anatomic resections, 105, 109
Anterior approach technique (AA), 4, 117
Ante situm technique, 125
Aortic jump graft, 262f
Appleby procedure, 297, 305, 306, 307, 308f
Arterial anomalies, 290
Arterial reconstruction, 183, 185
Alanine aminotransferases (ALT), 128, 132,
179
Aspartate aminotransferases (AST), 128, 132,
179
Aspirin, 381, 423
Associating liver partition and portal vein
ligation for staged hepatectomy
(ALPPS), 49, 61–62, 65
hybrid ALPPS, 62
mini-ALPPS, 58, 62, 64
Associating liver tourniquet and portal ligation
for staged hepatectomy (ALTPS), 61
Azygos-hemiazygos system, 149
B
Barcelona clinic liver cancer (BCLC), 10, 88
B.E. S.A.F.E. mnemonic, 208
Beger’s procedure, Frey modification of, 394
Belghiti-hanging maneuver, 4–7
direction and position for clamp during, 6f
Bi-ductal Roux-en-Y hepatico-jejunostomy,
241
Bilateral multifocal colorectal liver metastases,
ALPPS, 57
case presentation, 57–58
diagnosis and assessment, 59
management, 58, 60–63
outcome, 63–67
Bilateral multifocal colorectal liver metastasis,
two-stage approach, 39
case presentation, 40–42
outcome of two-stage hepatectomy and its
current role, 49–52
preoperative assessment, 42–43
surgical management, 43–49
Bilateral subcostal incision, 265, 406f
Bile duct, 167, 169, 171f, 172
Bile duct cysts, 218f
Bile duct disconnection, 240
© Springer International Publishing AG 2017
T.M. Pawlik et al. (eds.), Case-Based Lessons in the Management of Complex
Hepato-Pancreato-Biliary Surgery, DOI 10.1007/978-3-319-50868-9
451
452 Index
Bile duct injury at hepatic confluence, 227, 236
construction of neoconfluence, 231
double barrel anastomosis, 230
liver transplantation, 232
MRI showing loss of confluence, 228f
partial hepatectomy, 231–232
portoenterostomy, 229–230
Bile duct time-out, 208, 209
Biliary drainage, 34, 219, 240, 246
percutaneous transhepatic drainage, 179
Biliary systems, 248
Bilio-enteric anastomosis, 330
Bipolar devices, 116
Bismuth–Corlette classification for bile duct,
171f, 173
Bleeding, 3, 4, 9, 27, 79
Bleeding risk, operative, 357
Borderline resectable pancreatic
adenocarcinoma, 279
Borderline resectable pancreatic ductal
adenocarcinoma, 289
Bowel ischemia and necrosis, 380
Branch-duct type intraductal papillary
mucinous neoplasm (BD-IPMN),
361–362, 366–368
BRCA2, 324
Broad-spectrum antibiotics, 432
Bypass circuit, 126
C
Cambridge classification systems, 387–389,
417
388t,
Cancer antigen 19-9 (CA19-9), 325
Cantlie’s line, 113
CAPOX (doublet), first-line therapy, 60
Carbohydrate antigen 19-9 (CA 19-9), 375,
377
Carcinoembryonic antigen (CEA), 57, 95, 96,
128
Cattell–Braasch man, 305
Caval involvement, 113
Cavernous transformation, 378, 381
Celiac artery (CA), 375
Central hepatectomy, 34, 34f
Centrally located liver tumor. See Resection of
centrally located
cystadenoma/cystadenocarcinoma
Central Pancreas Consortium (CPC), 318
Central venous pressure (CVP) anesthesia
approach, 97
“Chain-of-lakes” appearance of MPD, 393
Chen’s liver double-hanging maneuver, 7
case presentation, 9
diagnosis and assessment, 10–13
during surgery, 8f
management, 10, 13–14
outcome, 14
right hemi-hepatectomy with, 14f
Child-Pugh scoring system, 12
Cholangiocarcinoma, 220, 237, 239, 259, 260,
264
CT volumetry of, 129f
deceased donor liver transplant for, 263f
living donor liver transplant for, 269f
non-metastatic hilar, 264f
Cholangiogram, 246, 402
Cholangiography, 211, 254
Cholangioscopy, 238, 241
Cholangitis, 171, 221, 236
Cholecystectomy, 113, 202, 207, 209, 210,
227, 415
Choledochal cysts, 215, 217, 220
incidence and aetiology, 219
Todani classification of, 218, 218f
Chronic obstructive pulmonary disease
(COPD), 401
Chronic pancreatitis (CP), Puestow and Frey
procedures, 385, 395f
Cambridge classifi cation systems, 387–389
etiology, 386
Marseille classifi cation systems, 387–389
operative techniques, 393–396
Frey modification of Beger’s procedure,
394
outcomes and pitfalls, 395–396
Puestow, 393–394
pathophysiology, 387
preoperative evaluation for CP and dilated
MPD, 392
Rosemont classification systems, 387–
389
surgical treatment of, 389, 392
differential diagnosis, 389–390
workup, 391–392
Chronic pancreatitis, Frey procedure, 401
alcohol and smoking cessation, 404
case presentation, 401–402
diagnosis and assessment, 403–404
intraoperative technique, 405
exposure of pancreas, 405
longitudinal pancreatic ductotomy,
405–406
pancreatic head resection, 406–408
positioning and preparation, 405
postoperative management, 410
Roux-en-Y pancreaticojejunostomy,
408–409
management, 404–405
Ciprofloxacin, 443
Index 453
Clindamycin, 443
Collagenase, 420
Colon cancer, 59
Colorectal cancer, 96
Colorectal liver metastases (CRLM), 65, 66t,
73, 110, 112
Common bile duct (CBD), 215, 328
abdominal ultrasound images, 216f
gallbladder cancer with (see Gallbladder
cancer with common bile duct
invasion)
Common bile duct invasion. See Gallbladder
cancer with common bile duct
invasion
Common hepatic artery
(CHA), 290, 327, 375
Common hepatic duct (CHD), 215
Complete caudate lobe replacement from
tumor, 133f
Complications
of pancreatic necrosis, 438–439
of TPIAT, 424
Computed tomography (CT), 10, 57, 59, 179
diagnosing bilateral multifocal colorectal
liver metastasis, 42
enterography (CT enterography), 167
for patient with HCC, 11f
Concurrent chemoradiotherapy, 170
Contralateral bile duct injury, management
after liver resection, 245
discussion, 252
initial management, 254
operative management, 255
initial presentation and workup, 252–254
prevention of contralateral bile duct injury,
255–256
Contrast-enhanced imaging
CT, 110, 179, 432
MRI, 97, 167
Coronary artery bypass graft (CABG),
245
CUSA (ultrasonic dissector), 90, 117
Cyst excision and reconstruction, 221
Cystadenocarcinoma, 29
Cystadenoma, 29
Cystadenoma/cystadenocarcinoma, centrally
located, 29
resection of (see Resection of centrally
located
cystadenoma/cystadenocarcinoma)
Cyst(o)gastrostomy, 435, 447, 439
Cystotomy, 443
D
Da Vinci surgical system, 101
Debulking of extensive neuroendocrine liver
metastases, 17
NET metastatic to liver
mid-gut NET, 18–22
pancreas NET, 23–25
overall management of patients with
extensive neuroendocrine hepatic
metastasis, 25
technical pearls for, 22
Delayed gastric emptying (DGE), 306
Diabetes
and acute pancreatitis, 417–418
and gangrenous gallbladder, 205
Diffuse small duct pancreatitis, 413, 417f
Diffusion-weighted MRI (DW-MRI), 59
Dilated pancreatic duct, 393
Distal pancreatectomy, 303, 307, 357–358
Donation after cardiac death (DCD), 265
Doppler ultrasound, 143, 156
Double barrel anastomosis, 230
Double-hanging maneuver, 4
Chen’s double-hanging maneuver, 7–15
modified, 10f
Ductal dilation, 390
Ductal hypertension, 387
Ductal stenosis, 390
Ductotomy,
394, 405, 409
Duct-to-mucosa modified-Blumgart
pancreaticojejunostomy technique,
330
Duodenojejunostomy, 330
Duplex ultrasonography, 191
E
ECOG (Eastern Cooperative Oncology Group)
performance status, 187, 377, 378
Emphysematous cholecystitis, 206
Endo GIA Universal Stapling System, 113
Endoscopic debridement, 433
Endoscopic necrosectomy, 434–435
Endoscopic retrograde cholangiography
(ERC), 169, 217
Endoscopic retrograde
cholangiopancreatography (ERCP),
189f, 227, 238, 324, 391, 402, 413,
414, 417, 439
Endoscopic transgastric drainage, 435
Endoscopic ultrasound (EUS), 238, 311, 317,
325, 375, 388, 391, 403, 414, 434
and fine needle aspiration (EUS-FNA), 361
Endoscopy, 299, 300
Enhanced recovery after surgery (ERAS)
pathway, 330
Enucleation technique, 36–37
454 Index
Esophagogastroduodenoscopy (EGD), 311
Estimated total liver volume (eTLV), 47
European Society of Enteral and Parental
Nutrition (ESPEN), 13
Ex vivo liver resection, 124–127
case 1, 127–132
case 2, 132–137
Extended hepatectomy, 172, 185
Extra-hepatic cyst excision, 221
F
Familial atypical multiple mole melanoma
syndrome (FAMMMS), 324
Favorable disease biology, 302
Fecal fat excretion, 391
Fibro-inflammatory syndrome, 403
Fine needle aspiration (FNA), 278, 375
EUS-FNA, 361
Fluorine 18-fluorodeoxyglucose (18F-FDG)
PET-CT, 59, 76, 143
5-Fluorouracil (5-FU), 260
5 French KMP catheter, 420
Fluorescence in situ hybridization (FISH), 169,
269
Fluoroscopic sonogram, 439
Fluorouracil, 303
Focal intrahepatic strictures, 236
management options, 240
FOLFIRI (doublet), first-line therapy, 60
FOLFIRINOX (triplet) chemotherapy, 279
FOLFOX (doublet), first-line therapy, 58, 60,
64, 78
FOLFOXIRI (triplet),
first-line therapy, 60
14 French percutaneous drain, 435, 428f
Fresh frozen plasma (FFP), 131
Frey modification of Beger’s procedure, 394
Future liver remnant (FLR), 10, 12, 39–40, 48,
59, 60
/standardized liver volume (SLV) ratio, 11
G
Gallbladder adenocarcinoma, 190, 194
disease-specific survival for, 195f
Gallbladder cancer with common bile duct
invasion, 187
case presentation, 187–190
disease-specific survival (DSS), 192–193,
195f
FDG-PET imaging, 191
management of, 193–196
operative principles, 196–198
PET imaging, 191–192
radiographic assessment of locally
advanced gallbladder carcinoma,
191–192
surgical management, general principles of,
192–193
Gangrenous cholecystitis, 204, 211
Gangrenous gallbladder, management of, 201
antibiotic therapy for, 202, 207
approaches, 203–204
case presentation, 201–203
diagnostic imaging, 205–206
gallbladder wall enhancement, 202f, 203f
initial presentation, 204–205
management, 207–208
surgical considerations,
208–211
Tokyo Guidelines, 206
Gastric antrum, 444
Gastrocolic approach, 438
Gastrocolic ligament, 393
Gastroduodenal artery (GDA), 292, 304, 327,
405
Gastrojejunostomy, 330, 438
Gastrotomy, 435
Gd-EOB-DTPA, MRI contrast agent, 43
Gemcitabine
and cisplatin (Gem/Cis), 170
/nab-paclitaxel, 375
Gerota’s fascia, 314
Glissonian approach, 48
GoreTex, 124, 131
Grade II, moderate cholecystitis, 206
H
Hand-assist ports, 112, 116
Hand-assisted laparoscopic surgery (HALS),
89
Handsewn gastrojejunostomy, 330
Hanging maneuver, 117
Hasson technique, 312
Head-dominant disease, 396
Hemorrhage, 378, 438, 441
Heparin, 422, 423
Heparin injections, 381
Hepatectomy, 172, 192, 196
partial, 231–232
treatment algorithm for, 88f
Hepatic artery
accessory right hepatic artery (ARHA), 290
common hepatic artery (CHA), 290
replaced common hepatic artery (RCHA),
293f
replaced right hepatic artery (RRHA), 290,
293
Index 455
Hepatic confluence, bile duct injury at. See Bile
duct injury at hepatic confluence
Hepatic duplex ultrasound imaging, 191
Hepatic ischemia, 306
Hepatic reserve, 86, 88
Hepatic vein confluence, 125
Hepatic vein reconstruction, 129
Hepaticojejunostomy, 197, 221, 223
Hepatitis B virus (HBV) DNA, 9, 10, 14
Hepatocellular carcinoma (HCC), 3, 10, 85–86
diffuse-type HCC, 86
Hepato-Pancreatic-Biliary (HPB) Surgery
Center, 236
Hereditary pancreatitis, 414
5HIAA (5-Hydroxyindoleacetic acid), 18, 21
Hilar cholangiocarcinoma (HC), 259
with hepatic artery involvement, 179
case presentation, 179–180
intraoperative pictures, 183f
parenchymal transaction, 182–183
percutaneous transhepatic portal
embolization, 181f
preoperative computed tomography,
180f
surgery and outcomes, 181–186
with portal vein involvement, 167
Bismuth–Corlette classifi cation, 171f,
173, 175f
case presentation, 167
diagnosis and assessment, 168–169
management and outcomes, 170
–176
portal venous reconstruction, 173
transplantation for, 259
discussion, 264–267, 269–270
Mayo Clinic Protocol, 260f
Histidine–tryptophan–ketoglutarate (HTK),
125, 126
Hybrid ALPPS, 62
Hyperbilirubinemia, 246
Hypertriglyceridemia, 427
Hypoechoic tumor, CT axial image of, 376f
Hypothermic perfusion techniques, 148–150
I
Idiopathic chronic pancreatitis, 390
IgG-4 cholangiopathy, 169
Indocyanine green (ICG) clearance, 87
Inferior vena cava (IVC), 4, 5, 6, 113
chronic obstruction of, 143
dissection of anterior plane of, 5
infrahepatic, 126
partial resection of, 109
resection and reconstruction, 110, 148–150
retrohepatic, 141–142
suprahepatic, 126
surgery of, 145–146
vascular control of, 146–147, 147f
vascular exclusion of, 147
In situ cold perfusion, 125
In situ hypothermic perfusion, 154–157
International normalized ratio (INR), 246
International Study Group of Pancreatic
Surgery (ISGPS), 280
International Study Group on Pancreatic Fistula
(ISGPF), 410
Interventional radiology techniques,
25
Intestinal/colonic ischemia, 439
Intra-abdominal compartment syndrome, 439
Intracaval extension, staging of, 143–144
Intraductal calculi, 390
Intraductal papillary mucinous neoplasm
branch-duct type (BD-IPMN), 361–362,
366–368
main-duct (MD-IPMN), 362
Intraductal ultrasound (IDUS), 238
Intrahepatic biliary cystadenocarcinoma
(IBCC), 29
Intrahepatic biliary cystadenoma (IBC), 29, 36
Intrahepatic cystic disease, 217
Intraoperative ultrasonography (IOUS), 44, 48,
115, 116f
Intraoperative ultrasound-guided dissection, 20
Irinotecan, 303
Ischemic bowel, 439
Islet autotransplantation, 415, 417
J
Jejunostomy tube, 380
Jejunum, 327, 408
K
Ki-67 indices in liver metastases, 24
Klatskin tumor, 254
Kocher maneuver, 379, 408, 419
L
Laparoscopic cholecystectomy, 235, 236, 413
Laparoscopic cystgastrostomy, principles of,
447
Laparoscopic distal pancreatectomy (LDP),
311
Laparoscopic hemihepatectomy for
hepatocellular carcinoma, 85
case presentation, 85
computed tomography imaging, 86f
diagnosis and assessment, 85–88
hybrid technique, 89
intraoperative view, 91f
456 Index
Laparoscopic hemihepatectomy for
hepatocellular carcinoma (cont.)
magnetic resonance imaging, 87f
management, 88–89
outcome, 90–92
Laparoscopic hepatectomy, 13, 89
Laparoscopic liver resection (LLR), 88–89, 90,
109
Laparoscopic liver surgery, 101, 109–110
Laparoscopic major hepatectomy, 89
Laparoscopic transgastric necrosectomy, 435,
436f
Laparoscopic ultrasound, 115
Laparoscopy, 378, 444
Laparotomy, 240, 241f, 439
Large-caliber drains, 438
Late-onset disease, 390
Lateral pancreaticojejunostomy, 404
Left lateral sectionectomy, 99
Left-sided hepatectomy, 185
Leucovorin, 303
Liver ablation, 20, 22
Liver cancer necessitating ex vivo resection
and reconstruction, 123
case 1, 127–132
case 2, 132–137
ex vivo resection, 124–127
Liver double-hanging maneuver, 4, 7f
Chen’s double-hanging maneuver, 7–15
Liver failure, 59, 64
Liver function tests (LFTs), 85
Liver-hanging maneuver (LHM), 3, 4
Belghiti-hanging
maneuver, 4–7
Chen’s double-hanging maneuver, 7–15
Liver metastases from renal cell carcinoma,
160
after right nephrectomy and IVC tumor
resection, 153
Liver regeneration, 60
Liver resection, 19, 22, 88–89, 124
for bilateral multifocal colorectal liver
metastasis, 43
Liver transplantation, 232
Liver tumor, 3, 34, 36, 124, 158
Locally advanced gallbladder carcinoma,
radiographic assessment of, 188f,
189f, 191–192
Locally advanced pancreatic cancer, 377
Locally advanced PDA, 300, 302
Long-course radiation therapy (LCRT), 79–80
Long-term pain control, 396
Longitudinal pancreatic ductotomy, 405–406,
408f
Low rectal cancer with synchronous liver
metastases, management of, 73
case presentation 1, 73–74
case summary, 74–75
multidisciplinary management, 74
case presentation 2, 76
case summary, 77
multidisciplinary management, 76–77
case presentation 3, 78
case summary,
79
multidisciplinary management, 78
neoadjuvant therapy, 79–80
surgical resection, 80–81
symptomatic primary tumors, 79
Lumen-opposing expandable stents, 449
Lumen-opposing metal stent, 434, 435
Lynch syndrome, 324
Lysis of adhesions, 393
M
Magnetic resonance (MR), 205–206
Magnetic resonance cholangiopancreatography
(MRCP), 167, 187, 191, 216, 217f,
227, 238, 239f, 403, 414, 416, 439
Magnetic resonance imaging (MRI), 43, 299,
311, 316, 348
bilateral multifocal colorectal liver
metastases, 58
ill-defined lesions, 87f
for thrombus evaluation, 143
Main-duct intraductal papillary neoplasm
(MD-IPMN), 362
Main pancreatic duct (MPD), 362, 363f, 365,
368, 369, 370
in chronic pancreatitis, CT of, 393f, 417f
pancreatic fistulae, 439
Major laparoscopic liver resection,
complications after, 118
Marseille classification systems, 387–389
Marshall scoring system, 429, 430t
Memorial Sloan Kettering Cancer Center
(MSKCC), 191
Meso-axial hepatectomy, 252
Mesocaval shunt, 377, 378, 380, 381
Mesohepatectomy, 252
Metastases
colorectal liver metastases, 65, 66t, 73, 110,
112
liver metastases from renal cell carcinoma,
160
low rectal cancer with synchronous liver
metastases (see Low rectal cancer
with synchronous liver metastases,
management of)
Index 457
mFOLFIRINOX (combination cytotoxic
chemotherapeutics), 303, 304
Michel classification, 291f
Midgut carcinoid, 19, 25
Midgut neuroendocrine tumor metastatic to
liver, 17, 18–22
post-treatment photographs of, 21f
Mini-ALPPS, 58, 62, 64
Minimally invasive distal pancreatectomy
(MIDP), 318
Minimally invasive resection of colorectal liver
metastases, 95
case presentation, 95
epidemiology, 96
hepatic resection, 98–102
management, 98
outcomes, 103
PET-CT scan, 95
preoperative planning, 97
Minimally invasive surgical (MIS) approaches,
327
Mirizzi syndrome, 235, 236
Mirizzi Type II syndrome, 235
Modified Appleby procedure, 297, 304–306
Molecular adsorbents recirculating system
(MARS) therapy, 137
Multidetector computed tomography (MDCT),
143, 144, 316
Multifocal branch-duct intraductal papillary
mucinous neoplasm (multifocal
BD-IPMN), 361, 362–365
case presentation, 361
clinical management of, 365–370
partial pancreatectomy and postoperative
surveillance, 367–368
total pancreatectomy, 366–367
Multimodal pain regimen, 380
N
Narcotic weaning, 424
National Comprehensive Cancer Network
(NCCN) guidelines, 280
Necrotic tissue, 434
Neoadjuvant radiotherapy, 266
Neoadjuvant therapy, 79–80, 377
Neoconfluence, construction of, 231, 231f
Neuroendocrine tumors (NET), 17
Nociceptors, 387
Non-anatomical and anatomical liver
resections, 123
Nonneoplastic simple biliary cysts, 29
Norepinephrine, 428
“No-touch” technique, 171
Nuclear medicine imaging, 25
Nutrition risk index (NRI), 13
O
Obstructive jaundice, 193–195
Omega-3 fatty acid-based parenteral nutrition,
13
On-table choledochoscopy, 221
Open cholecystectomy, 204, 208, 210
Open distal pancreatectomy (ODP), 318
Overall management, extensive
neuroendocrine hepatic metastasis,
25
Oxaliplatin, 303
P
Painless pancreatitis, 391
Palliative chemotherapy, 79
Pancreas
exposure of, 405
neuroendocrine tumors (see also Pancreatic
neuroendocrine tumor (PNET)), 24,
339, 347, 348, 353
metastatic to liver, 17, 23–25
Pancreas injury, mechanisms of, 387
Pancreatectomy, 303, 378, 439
with celiac resection, 304
Pancreatic adenocarcinoma, 277, 416
diagnosis and workup, 277–278
intra-operative
approach, 282–284, 284f
management, 279–280
post-operative course, 285
pre-operative planning, 278, 280–282
Pancreatic adenocarcinoma, laparoscopic
approaches, 311
case presentation, 311
alternative techniques, 315–316
laparoscopic distal pancreatectomy,
operative technique for, 312–315
hypo-enhancing mass, 312f
postoperative care, 317
surveillance, 317
preoperative evaluation, 316–317
transection of pancreas with stapler, 314f
Pancreatic adenocarcinoma, robotic
approaches, 323
adjuvant therapy, 333
posttreatment surveillance and interval
staging, 333
case presentation, 324
epidemiology, 324
diagnostic workup and staging,
325–326
management, 326–327
458 Index
Pancreatic adenocarcinoma, robotic approaches
(cont.)
perioperative outcomes following robotic
PD, 331–333
robotic pancreaticoduodenectomy, 327–331
Pancreatic cancer, 286, 323, 348, 416
case presentation, 375–376
diagnosis and preoperative management,
376–378
multimodality management of, 377
postoperative care, 380–381
surgical management, 378–380, 379f
Pancreatic debridement, open, 437–438
approaches to, 438
goals of, 437
Pancreatic drainage procedure, 393
Pancreatic duct, 405
chronic pancreatitis in, 394f
computed tomography of, 393
Pancreatic duct decompression, 387, 397
Pancreatic duct pressures, 387
Pancreatic ductal adenocarcinoma (PDA), 297,
324
case presentation, 298
diagnosis of, 300–302
operative management, 304–306
pancreatic cancer staging, 301t
peri-operative care, 306–307
postoperative care and considerations for
follow-up, 307–309
preoperative management, 302–304
staging system, 300–302
workup, 298–
299
Pancreatic ductal anatomy, 439
Pancreatic enzyme replacement therapy, 418
Pancreatic enzyme supplementation, 404
Pancreatic exocrine dysfunction, 403
Pancreatic fistula, 315, 439
Pancreatic head tissue, 394
Pancreatic infection, 431
Pancreatic neck tumor, 378
Pancreatic necrosis, 427, 428f
case presentation, 427–429
management of, 432–434
complications, 438–439
endoscopic necrosectomy, 434–435
laparoscopic transgastric necrosectomy,
435
open pancreatic debridement, 437–438
video-assisted retroperitoneal
debridement, 435–437
medical therapy, 430
nutrition, 431
prophylactic antibiotic, 431
operative intervention, 433
pathophysiology and determination of
severity, 429
patterns of, 434f
Pancreatic neuroendocrine tumor (PNET), 339,
353
case presentation, 353–355
case studies, 340–344
computed tomography (CT), 342f, 348
gastric varices secondary to sinistral
hypertension, 355f
pancreatic tail mass, 354f
discussion, 346–349
imaging of, 356
magnetic resonance imaging, 348
demonstrating splenic vein thrombosis,
f
354
operative planning, 356
operative technique, 357
postoperative management, 359
presentation, 355
results, 344–346
Pancreatic perfusion, 432
Pancreatic pseudocyst, 390, 441, 445f
formation, 403
management of, 446, 448
symptoms, 441
Pancreatic sensation, 387
Pancreat(ic)oduodenectomy (PD), 279, 289
Pancreat(ic)ojejunostomy, 393, 396, 408, 409,
410, 439
anterior view, 409f
Pancreatitis, acute
hemorrhage in, 438
IV antibiotics for prophylaxis for, 432t
Pancreatogram, 388, 402
Pancreatolithiasis. See Intraductal calculi
Pancreatosplenectomy. See Radical antegrade
modular pancreatosplenectomy
(RAMPS) technique
Parenchymal dissection, 117
Parenchymal-sparing techniques, 60
Parenchymal transaction, 44
Partial parenchymal transection (PPT), 62, 64
Partial resection of inferior vena cava, 109
case description, 110
caval involvement, 113
contrast-enhanced CT, 111f
histological analysis and postoperative
course, 114
patient positioning, 110, 112f
surgery, 113
technical alternatives, 115
control of hemorrhage, 116
Index 459
control of hepatic outflow, 117–118
haemostasis, drain and specimen
extraction, 118
parenchymal dissection, 117
postoperative complication, 118
transection without mobilization of right
lobe, 117
trocar placement, 110–113
ultrasound, 115
Percutaneous cholecystostomy, 207, 210
Percutaneous gallbladder drainage, 207
Percutaneous transhepatic biliary drainage
(PTBD), 179
Percutaneous transhepatic cholangiography
(PTC), 169, 217, 238, 246, 249
Perihilar cholangiocarcinoma, 185
Peutz–Jeghers syndrome, 324
Pfannestiel incision, 313f, 314, 315
Pigtail plastic stents, 434
Platelet-activating factor (PAF), 429
Pneumoperitoneum, 329
Porta hepatis, 173
Portal vein (PV), 346–347, 381
Portal vein embolization (PVE), 45, 46, 60, 61,
62–63, 174, 181f
Portal vein ligation (PVL), 45, 60, 61
Portal vein occlusion (PVO), 46–47, 61, 65
Portal vein resection,
123, 175, 279
Portoenterostomy, 229–230
Posterior right
disconnected bile duct, 235
multidisciplinary evaluation and operative
treatment, 240–242, 241f
preoperative assessment, 236
diagnostic tools, 238
endoscopic procedures, 238–240
malignant causes, 237
radiological assessment, 239
tissue sampling, 238
Pre-intervention hemorrhage, 438
Primary sclerosing cholangitis (PSC), 169, 259,
264, 269
Pringle’s maneuver, 44, 90
Prophylactic antibiotics, 378, 431
Protein induced by vitamin K absence or
antagonist II (PIVKA-II), 85–86
Proximal transection, 196
PRSS1 gene, 416
Pseudoaneurysm (PSA), 438, 439
Pseudocyst cavity, 444
PTFE (polytetrafluoroethylene), 149, 150f
Puestow-Gillesby procedure, 393
Puestow procedure, 393–394
Q
Quality of life, 25, 88, 105, 118, 366
Short Form questionnaire, 424
R
Radical antegrade modular
pancreatosplenectomy (RAMPS)
technique, 311, 315
Radical nephrectomy with tumor
thrombectomy, 152
Radiofrequency ablation (RFA), 39, 49
Radiofrequency-assisted liver partition with
portal vein ligation (RALPP), 61
Radiographic imaging, 415–416
Recurrent acute pancreatitis, 403, 414–415
Remnant liver function, 86
Renal cell carcinoma (RCC), resection of, 141
first case presentation, 141
adjunct procedures, 148
clinical presentation, 142
diagnosis and assessment, 143
IVC resection and reconstruction,
148–150
long-term outcome, 152
carcinoma with tumor thrombus
extending into retrohepatic IVC,
141–142
short-term outcome, 151
staging of intracaval extension,
143–144
surgery of IVC and hepatic veins,
145–146
surgical incisions, 145
surgical strategy, 144
vascular control of IVC, 146–147
second case presentation, 153
anesthetic management, 153
liver metastases after right nephrectomy
and IVC tumor resection, 153
long-term outcome, 160
short-term outcome, 158
surgical strategy, 153
TVE, venovenous bypass, and in situ
hypothermic perfusion, 154–157
Replaced common hepatic artery (RCHA),
293f
Replaced right hepatic artery (RRHA), 290,
293
and pancreatoduodenectomy, implications
of, 289
anatomical considerations, 290
preoperative considerations, 290–291
surgical considerations, 292–293
460 Index
Resection of centrally located
cystadenoma/cystadenocarcinoma,
29
anatomical considerations, 34–36
case 1, 30
history, 30
outcome, 32
procedure, 30–31
case 2, 32
history, 32
outcome, 33
procedure, 33
determining the approach, 37–38
discussion, 34
enucleation technique, 36–37
Residual pseudocyst, 443f
Retroperitoneal adipose, 442
Retroperitoneum, 433
Right coronary ligament, 7
Right hepatectomy, 3, 4, 9, 110
Right portal vein ligation, 46f
Right posterior biliary ducts, 236
Robotic-assisted pancreaticoduodenectomy,
330f
standard port placement for, 328f
Robotic-assisted right and left anatomic
lobectomy, 99, 100f, 104t
Robotic pancreaticoduodenectomy, 327–331
perioperative outcomes, 331–333
Rommel tourniquet, 380
Rosemont classification systems, 387–389,
389t
Roux-en-Y, 197, 221
Roux-en-Y cyst-jejunostomy, 448
Roux-en-Y gastrojejunostomy, 420, 422
Roux-en-Y hepaticoenterostomy,
255
Roux-en-Y hepaticojejunostomy, 221, 227
Roux-en-Y jejunal limb, 270
Roux-en-Y pancreaticojejunostomy, 408–409
Roux-en-Y reconstruction, 394
Roux limb, 408
S
Salvage pancreatectomy, 414
Segment IVb/V liver metastasis, 98
Sentinel acute pancreatitis event (SAPE), 390
Short-course radiotherapy (SCRT), 74, 79–80
Sinistral portal hypertension, 435
Small bowel neuroendocrine tumor (SBNET),
18, 18f
Small-duct chronic pancreatitis, 396
Smoldering pancreatitis, 390
SPECT/CT imaging, 59, 65f
Splenectomy, 357–358, 439
Splenic artery (SA), 375
Splenic vein (SV), 339, 444
Splenic vein thrombosis (SVT), 357, 390
Stapler devices, 117
Steatorrhea, 403, 404
Stereotactic body radiotherapy (SBRT), 279
Sterile necrosis, 433
Streptococcus constellatus, 443
Stricture, 246
Subjective Global Assessment (SGA), 13
Subtotal cholecystectomy, 209, 210
Superinfection, 432
Superior mesenteric artery (SMA), 280, 327,
329, 379
Superior mesenteric-portal vein (SMPV), 280,
282
Superior mesenteric vein (SMV), 279, 280,
, 328–329, 339, 346–347, 379,
282
406
Superior mesenteric vein–portal vein–splenic
vein confluence (SMV-PV-SVV),
375
Suprahepatic inferior vena cava, control of,
145f
Surgical incisions, 145
Surgical therapy, 392
goal of, 392
Symptomatic primary tumors, 79
Symptomatic pseudocysts, 442, 447
Synchronous hepatic resection, 221
Systemic chemotherapy, 78
Systemic heparinization, 380
Systemic inflammatory response syndrome
(SIRS), 427
T
Thompson retractor, 393
TIGAR-O classification system, 403
Tissue thromboplastin, 424
Tobacco, 415
Tokyo Guidelines (TG), 206
Total liver volume (TLV), 47
Total pancreatectomy with islet
autotransplantation (TPIAT),
413–424
case scenarios
diffuse small duct disease, 413
hereditary pancreatitis, 414
recurrent acute pancreatitis, 414–415
salvage pancreatectomy, 414
long-term outcomes, 424
patient selection criteria, 419
postoperative care, 423–424
pain control, 424